Direct-to-Patient (DtP): The Future of Clinical Trials in India

Key Takeaways

The Retention Revolution: Logistical difficulties and travel are primary reasons for high patient dropout rates in India. Moving the clinical site to the home removes this significant barrier.

New Drugs and Clinical Trials (NDCT) Rules, 2019: India’s regulatory framework, overseen by the CDSCO, is evolving to support decentralised trials. These rules demand a robust, quality-driven approach to trial management.

Unbroken Chain of Custody: Maintaining the stability of unapproved medicines outside a clinical setting requires proven technologies like IoT sensors and specialised, white-glove delivery services.

Scalable Compliance: Success in India means navigating a complex regulatory landscape and reaching diverse patient populations, including those in remote locations, with a partner who understands the intricacies of local compliance.

Traditional site-centric models of research are hitting a wall in 2026. Recruitment goals are frequently missed because patients cannot manage the time and travel required for hospital visits. We've built the DHL Health Logistics network to solve this challenge directly. Our 2-billion-euro investment ensures you have the GDP-certified infrastructure and specialised handling needed to reach patients anywhere in India. Direct-to-Patient (DtP) clinical trials move the laboratory to the living room while maintaining the highest levels of safety and regulatory compliance.

Why is patient retention the biggest risk in 2026 clinical research?

Travel and logistical burdens are major reasons participants leave clinical studies in India. When you move the trial site to the patient, you reduce missed visits and screen failures, which directly impacts data integrity.

Travel Distance: Cancer trial patients travel a median of nearly 42 miles for Phase I studies.

Rural Hurdles: For India’s vast rural population, participants in remote areas often face significant travel challenges, sometimes travelling over 100 miles each way.

Human Connection: Technical couriers act as a professional and reassuring extension of the clinical site at the participant's doorstep.

Supportive Experience: White-glove services go beyond simple delivery to build the participant trust that is essential for retention in the Indian cultural context.

DHL Health Logistics provides the professional bridge between your lab and the participant. We understand that a courier is often the only face of the trial that a patient sees, making their professionalism critical to the study's success.

What are the 2026 regulatory requirements for DtP?

Regulators in India, led by the Central Drugs Standard Control Organization (CDSCO), are continually refining rules to support decentralised models under the New Drugs and Clinical Trials (NDCT) Rules, 2019. A key requirement is to prove the drug remained stable from the depot to the patient’s refrigerator.

Evolving Guidelines: While India aligns with global best practices like ICH GCP, sponsors must adhere to the specific requirements of the NDCT Rules, which emphasise data integrity and participant safety.

Strict Accountability: The CDSCO requires comprehensive records proving temperature stability throughout the entire supply chain. This means logistics providers must offer a complete audit trail for every shipment.

Thermal Protection: Advanced shippers maintain critical temperature ranges, such as 2 to 8°C or -20°C, for up to 120 hours, essential for covering vast distances from a central depot to a patient's home.

Digital Proof: IoT sensors transmit live data, providing verifiable proof of when the participant received the shipment and that its temperature remained within the specified limits.

Our investment in digital tools ensures you have a full thermal audit trail. This level of transparency is a mandatory requirement for satisfying both regulatory authorities and quality assurance teams in 2026.

How do you handle medical license restrictions in emerging markets?

Delivering unapproved medicines to a private address is strictly regulated in India. You need a partner who has deep expertise in navigating the permissions required by the CDSCO and the Central Board of Indirect Taxes and Customs (CBIC).

Health Reforms: India’s regulatory landscape for clinical trials is dynamic, with amendments to the NDCT rules streamlining processes while maintaining stringent oversight. Staying current is critical for compliance.

Import Permissions: Importing unapproved drugs for personal use in a trial requires specific licenses, such as those obtained via Form 12A, and a No Objection Certificate (NOC) from the CDSCO. This process ensures every shipment is legally compliant.

Expert Navigation: Our local specialists work closely with bodies like the CDSCO to ensure your trial documentation is precise and complete, preventing delays at major entry points like Delhi Airport.

Expanded Footprint: Proper licensing and logistics expertise allow you to reach patient populations in regions previously considered too complex, expanding the diversity and reach of your trial.

Can you guarantee a secure chain of custody at the doorstep?

Security and privacy are vital when delivering sensitive medical products to a home. The process must ensure the medicine is handed directly to the verified participant or their designated legal representative, in line with trial protocols.

Identity Verification: We check official identification against trial records before any package is handed over, ensuring the right person receives the medicine.

Point-of-Use Delivery: Where required, our couriers can place the medication directly into the participant’s designated storage area or refrigerator.

Instruction Support: We confirm the patient understands how to handle and store the packaging and investigational product correctly.

Safe Disposal: We are equipped to collect used kits or sharp containers for compliant, medical-grade destruction, closing the loop on the supply chain.

What is the role of reverse logistics in home-based trials?

A DtP trial does not end at the doorstep. Managing the reverse flow of biological samples and unused drugs back to the central lab is a critical component of data integrity and regulatory compliance.

Stability Windows: Biological samples like blood or urine must be collected and returned to the laboratory within strictly defined time and temperature limits to be viable.

Data Integrity: If a biological sample deviates from its required temperature range during transit, the resulting clinical data can be rendered invalid, jeopardising the trial's outcome.

Remote Reach: We use specialised transport solutions and packaging to reliably reach participants in geographically diverse locations across India and return samples securely.

Unified Visibility: A clinical research associate in Mumbai should see the same real-time tracking data as a sponsor in London, ensuring complete transparency across the entire trial.

Ready to streamline your clinical trial strategy?

Direct-to-Patient logistics is no longer just a future concept. It is a proven method to improve the patient experience, enhance retention, and protect the integrity of your data. DHL Health Logistics is ready to help you scale your research across India. Speak to a DHL specialist today to check your trial plan and reach your participants with confidence.

Frequently Asked Questions